Jianhua Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jianhua Zhang has a total of 86 co-authors. Here are the top co-authors by number of shared publications:
Xuhe Liao
Department of Nuclear Medicine, Peking University First Hospital, Beijing, China
6 shared publicationsXueqi Chen
Department of Nuclear Medicine, Peking University First Hospital, Beijing, China
5 shared publicationsYan Fan
Department of Nuclear Medicine, Peking University First Hospital, Xicheng District, Beijing, China
5 shared publicationsMeng Liu
Department of Nuclear Medicine, Peking University First Hospital, Beijing, China
4 shared publicationsShanshi Li
Department of Radiation Oncology, Peking University First Hospital, Beijing, China
4 shared publications- Yan Fan
Department of Nuclear Medicine, Peking University First Hospital, Beijing, China
4 shared publications
Latest Publications
- Open Access
- 8 December 2025
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 51 (2) , 99-107
Noninvasive Evaluation of HER2 Expression and Heterogeneity in Urothelial Carcinoma on 68Ga-HER2-affibody PET/CT
Purpose: Human epidermal growth factor receptor 2 (HER2) is a promising therapeutic target in urothelial carcinoma (UC). We aimed to evaluate the feasibility of 68 Ga-HER2 affibody PET/CT in assessing HER2 expression and tumor heterogeneity, and to explore its utility for guiding HER2-targeted therapy in UC. Patients and Methods: Thirty-two patients with UC who underwent 68 Ga-HER2-affibody and 18 F-FDG-PET/CT were prospectively recruited from September 2024 to April 2025. Semiquantitative PET/CT parameters (SUVmax, SUVmean, TMR, HER2-TV / MTV, and TL-HER2/TLG) were analyzed across HER2 statuses. Intrapatient heterogeneity of SUVmax across lesions was assessed by the coefficient of variation (CV). Results: HER2-positive patients demonstrated significantly higher SUVmax, SUVmean, TMR, and HER2-TV of 68 Ga-HER2-affibody PET/CT compared with HER2-negative patients (all P < 0.05). No significant differences were observed in 18 F-FDG PET/CT except for MTV and TLG ( P < 0.05). ROC analysis revealed strong predictive value for HER2-SUVmax (AUC: 0.87) and TMR (AUC: 0.88) in differentiating HER2-negative/positive. Stepwise increases in HER2-PET/CT parameters were observed across HER2 immunohistochemistry statuses ( P trend < 0.05). HER2-PET/CT demonstrated high heterogeneity, with a median SUVmax CV of 49.7% (IQR: 29.7%–64%) across intrapatient metastatic lesions. In 7 patients receiving HER2-target therapy, 2 patients with low HER2 uptake on PET/CT developed progressive disease, whereas 4 of 5 patients with high uptake achieved a partial response. Conclusions: 68 Ga-HER2 affibody PET/CT is a feasible method to detect the HER2 status and heterogeneity in UC patients noninvasively. This method provides a valuable tool for identifying patients who benefit from HER2-target therapy.
- 8 December 2025
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 51 (2) , 99-107
Open AccessNoninvasive Evaluation of HER2 Expression and Heterogeneity in Urothelial Carcinoma on 68Ga-HER2-affibody PET/CT
Purpose: Human epidermal growth factor receptor 2 (HER2) is a promising therapeutic target in urothelial carcinoma (UC). We aimed to evaluate the feasibility of 68 Ga-HER2 affibody PET/CT in assessing HER2 expression and tumor heterogeneity, and to explore its utility for guiding HER2-targeted therapy in UC. Patients and Methods: Thirty-two patients with UC who underwent 68 Ga-HER2-affibody and 18 F-FDG-PET/CT were prospectively recruited from September 2024 to April 2025. Semiquantitative PET/CT parameters (SUVmax, SUVmean, TMR, HER2-TV / MTV, and TL-HER2/TLG) were analyzed across HER2 statuses. Intrapatient heterogeneity of SUVmax across lesions was assessed by the coefficient of variation (CV). Results: HER2-positive patients demonstrated significantly higher SUVmax, SUVmean, TMR, and HER2-TV of 68 Ga-HER2-affibody PET/CT compared with HER2-negative patients (all P < 0.05). No significant differences were observed in 18 F-FDG PET/CT except for MTV and TLG ( P < 0.05). ROC analysis revealed strong predictive value for HER2-SUVmax (AUC: 0.87) and TMR (AUC: 0.88) in differentiating HER2-negative/positive. Stepwise increases in HER2-PET/CT parameters were observed across HER2 immunohistochemistry statuses ( P trend < 0.05). HER2-PET/CT demonstrated high heterogeneity, with a median SUVmax CV of 49.7% (IQR: 29.7%–64%) across intrapatient metastatic lesions. In 7 patients receiving HER2-target therapy, 2 patients with low HER2 uptake on PET/CT developed progressive disease, whereas 4 of 5 patients with high uptake achieved a partial response. Conclusions: 68 Ga-HER2 affibody PET/CT is a feasible method to detect the HER2 status and heterogeneity in UC patients noninvasively. This method provides a valuable tool for identifying patients who benefit from HER2-target therapy.
- 25 April 2025
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 52 (12) , 4399-4413
A visual whole-body tumor-burden classification based on PSMA PET/CT to predict response to novel androgen receptor signaling inhibitors for metastatic hormone-sensitive prostate cancer patients
Purpose The incidence rates of metastatic hormone-sensitive prostate cancer (mHSPC) have increased rapidly. Androgen deprivation therapy (ADT) with AR signaling inhibitors (ARSIs) has been determined survival benefit for mHSPC patients in several randomized trials. However, patients do not respond uniformly. Whole-body tumor-burden schemes guided by prostate-specific membrane antigen (PSMA) PET/CT have been proven to be a useful predictive tool for PSMA-targeted radioligand therapy (RLT), while the value for hormone therapy was unclear. We hypothesized a visual whole-body tumor-burden classification based on PSMA PET/CT can enable selective patient stratification and prognostic evaluation for hormone treatment. Materials and methods Patients diagnosed with de novo mHSPC through pathological test and [18F]F-PSMA PET/CT between February 2022 and December 2023 who received ADT alone or ADT plus first-generation antiandrogens or ADT plus second-generation/novel ARSIs in our hospital were included. Only can hormone treatments (ADT or ADT plus first-generation antiandrogens or ADT plus novel ARSIs) be adopted at least six months after initial diagnosis. Prostate Cancer Multidisciplinary Team (MDT) of our hospital proposed a newly visual whole-body tumor-burden scheme based on PSMA PET/CT (MDT scheme: high vs. low): MDT high group (fulfilling any one of the three following criteria): (I) the number of metastatic lesions is more than 10 (diffused involvement of single bone is counted as 4 lesions) and PSMA uptake levels of 80% lesions are higher than that of parotid glands, (II) the presence of visceral metastases, (III) at least 4 bone metastases (≥ 1 beyond the vertebral bodies or the pelvis). In addition, other three tumor-burden classification methods (PSMA-CHAARTED, PSMA-LATITUDE, revised-vPSG schemes) were also assessed in this study. A series of other parameters including SUV-derived features of PSMA PET/CT and potential clinical and pathological factors were evaluated. SUV-derived features were determined for measurable locations and included: SUVmax, SUVpeak, SUVmean and tumor volume (TV) of prostatic primary lesions, the highest SUVmax of all lesions in whole body (wbSUVmax), primary-tumor SUVmax ratio backgrounds (including blood pool of liver/ spleen/ mediastinum/parotid glands), wbSUVmax ratio backgrounds above. Serum prostate-specific antigen (PSA) lower than 0.2 ng/ml after six-month hormone treatment was set as the primary endpoint for prediction of PSA response. PSA99 (PSA reduction ≥ 99%) was the second endpoint for survival analysis. All parameters above including the four tumor-burden classification schemes were evaluated for the predictive and prognostic value according to the endpoints using logistic and Cox proportional hazards regression analysis, respectively. All P values < 0.05 were considered significant. Results A total of 165 patients were included. The average age was 69.30 ± 8.12 years. In univariate logistic regression analysis, MDT, PSMA-CHAARTED, revised-vPSG tumor-burden classifications, type of hormone treatment and primary-tumor TV were significantly related to PSA response, and PSMA-LATITUDE scheme wasn’t relevant to PSA response. The results of further multivariate logistic regression revealed MDT scheme (MDT high group vs. low group: OR = 5.34, 95%CI: 2.40–11.87, P < 0.001), type of hormone treatment (ADT + second-generation ARSIs vs. ADT alone or ADT + first-generation antiandrogens: OR = 0.21, 95%CI: 0.08–0.53, P = 0.001), and primary-tumor TV (≥ 12.49 cm3 vs. < 12.49 cm3: OR = 2.93, 95%CI: 1.25–6.89, P = 0.014) were proven to be independent significant predictors for mHSPC patients. Subgroups analysis of patients treated with ADT + second-generation ARSIs (N = 133) showed MDT, PSMA-CHAARTED, PSMA-LATITUDE, revised-vPSG tumor-burden classifications and primary-tumor TV were significantly associated with PSA response through univariate analysis, and in multivariate regression MDT scheme (MDT high group vs. low group: OR = 5.73, 95%CI: 2.47–13.30, P < 0.001) and primary-tumor TV (≥ 12.49 cm3 vs. < 12.49 cm3: OR = 2.75, 95%CI: 1.09–6.96, P = 0.032) were independent significant predictors for PSA response of novel ARSIs. The AUC of three-predictors model of 165 mHSPC patients was 0.740 (95% CI: 0.664–0.816, P < 0.001). The AUC of two-predictors model of 133 mHSPC patients treated with ADT + novel ARSIs was 0.751 (95% CI: 0.666–0.836, P < 0.001). Univariate survival analysis revealed that patients treated with ADT + second-generation ARSIs were prone to obtaining PSA remission in shorter period (P < 0.001). In multivariate Cox regression, MDT scheme (MDT high group vs. low group: HR = 0.52, 95%CI: 0.36–0.74, P < 0.001) and type of hormone treatment (ADT + second-generation ARSIs vs. ADT alone or ADT + first-generation antiandrogens: HR = 3.34, 95%CI: 2.02–5.54, P < 0.001) were demonstrated to be independent significant prognostic indicators of patients with mHSPC. The survival analysis of patients treated with ADT + second-generation ARSIs (N = 133), patients with low burden of MDT (P < 0.001) or PSMA-CHAARTED (P = 0.029) or PSMA-LATITUDE (P = 0.009) could achieve PSA 99% reduction faster, and the low and high group patients based on revised-vPGS weren’t displayed the significant difference in PSA99. Through the multivariate Cox survival regression, only MDT scheme (MDT high group vs. low group: HR = 0.47, 95%CI: 0.33–0.69, P < 0.001) was selected as the independent significant prognostic biomarker for mHSPC patients treated with ADT + second-generation ARSIs. Conclusion The visual whole-body tumor-burden classification based on PSMA PET/CT should be an effective stratification strategy for mHSPC patients treated with ADT + ARSIs, especially with ADT + second-generation ARSIs. PSA99 (PSA reduction ≥ 99%) could be a superior endpoint for patients with HSPC. This classification scheme could be a promising method for stratifying mHSPC patients. These findings need to be confirmed and validated through a longer follow-up, prospective and clinical data.
- 25 April 2025
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 52 (12) , 4399-4413
A visual whole-body tumor-burden classification based on PSMA PET/CT to predict response to novel androgen receptor signaling inhibitors for metastatic hormone-sensitive prostate cancer patients
Purpose The incidence rates of metastatic hormone-sensitive prostate cancer (mHSPC) have increased rapidly. Androgen deprivation therapy (ADT) with AR signaling inhibitors (ARSIs) has been determined survival benefit for mHSPC patients in several randomized trials. However, patients do not respond uniformly. Whole-body tumor-burden schemes guided by prostate-specific membrane antigen (PSMA) PET/CT have been proven to be a useful predictive tool for PSMA-targeted radioligand therapy (RLT), while the value for hormone therapy was unclear. We hypothesized a visual whole-body tumor-burden classification based on PSMA PET/CT can enable selective patient stratification and prognostic evaluation for hormone treatment. Materials and methods Patients diagnosed with de novo mHSPC through pathological test and [18F]F-PSMA PET/CT between February 2022 and December 2023 who received ADT alone or ADT plus first-generation antiandrogens or ADT plus second-generation/novel ARSIs in our hospital were included. Only can hormone treatments (ADT or ADT plus first-generation antiandrogens or ADT plus novel ARSIs) be adopted at least six months after initial diagnosis. Prostate Cancer Multidisciplinary Team (MDT) of our hospital proposed a newly visual whole-body tumor-burden scheme based on PSMA PET/CT (MDT scheme: high vs. low): MDT high group (fulfilling any one of the three following criteria): (I) the number of metastatic lesions is more than 10 (diffused involvement of single bone is counted as 4 lesions) and PSMA uptake levels of 80% lesions are higher than that of parotid glands, (II) the presence of visceral metastases, (III) at least 4 bone metastases (≥ 1 beyond the vertebral bodies or the pelvis). In addition, other three tumor-burden classification methods (PSMA-CHAARTED, PSMA-LATITUDE, revised-vPSG schemes) were also assessed in this study. A series of other parameters including SUV-derived features of PSMA PET/CT and potential clinical and pathological factors were evaluated. SUV-derived features were determined for measurable locations and included: SUVmax, SUVpeak, SUVmean and tumor volume (TV) of prostatic primary lesions, the highest SUVmax of all lesions in whole body (wbSUVmax), primary-tumor SUVmax ratio backgrounds (including blood pool of liver/ spleen/ mediastinum/parotid glands), wbSUVmax ratio backgrounds above. Serum prostate-specific antigen (PSA) lower than 0.2 ng/ml after six-month hormone treatment was set as the primary endpoint for prediction of PSA response. PSA99 (PSA reduction ≥ 99%) was the second endpoint for survival analysis. All parameters above including the four tumor-burden classification schemes were evaluated for the predictive and prognostic value according to the endpoints using logistic and Cox proportional hazards regression analysis, respectively. All P values < 0.05 were considered significant. Results A total of 165 patients were included. The average age was 69.30 ± 8.12 years. In univariate logistic regression analysis, MDT, PSMA-CHAARTED, revised-vPSG tumor-burden classifications, type of hormone treatment and primary-tumor TV were significantly related to PSA response, and PSMA-LATITUDE scheme wasn’t relevant to PSA response. The results of further multivariate logistic regression revealed MDT scheme (MDT high group vs. low group: OR = 5.34, 95%CI: 2.40–11.87, P < 0.001), type of hormone treatment (ADT + second-generation ARSIs vs. ADT alone or ADT + first-generation antiandrogens: OR = 0.21, 95%CI: 0.08–0.53, P = 0.001), and primary-tumor TV (≥ 12.49 cm3 vs. < 12.49 cm3: OR = 2.93, 95%CI: 1.25–6.89, P = 0.014) were proven to be independent significant predictors for mHSPC patients. Subgroups analysis of patients treated with ADT + second-generation ARSIs (N = 133) showed MDT, PSMA-CHAARTED, PSMA-LATITUDE, revised-vPSG tumor-burden classifications and primary-tumor TV were significantly associated with PSA response through univariate analysis, and in multivariate regression MDT scheme (MDT high group vs. low group: OR = 5.73, 95%CI: 2.47–13.30, P < 0.001) and primary-tumor TV (≥ 12.49 cm3 vs. < 12.49 cm3: OR = 2.75, 95%CI: 1.09–6.96, P = 0.032) were independent significant predictors for PSA response of novel ARSIs. The AUC of three-predictors model of 165 mHSPC patients was 0.740 (95% CI: 0.664–0.816, P < 0.001). The AUC of two-predictors model of 133 mHSPC patients treated with ADT + novel ARSIs was 0.751 (95% CI: 0.666–0.836, P < 0.001). Univariate survival analysis revealed that patients treated with ADT + second-generation ARSIs were prone to obtaining PSA remission in shorter period (P < 0.001). In multivariate Cox regression, MDT scheme (MDT high group vs. low group: HR = 0.52, 95%CI: 0.36–0.74, P < 0.001) and type of hormone treatment (ADT + second-generation ARSIs vs. ADT alone or ADT + first-generation antiandrogens: HR = 3.34, 95%CI: 2.02–5.54, P < 0.001) were demonstrated to be independent significant prognostic indicators of patients with mHSPC. The survival analysis of patients treated with ADT + second-generation ARSIs (N = 133), patients with low burden of MDT (P < 0.001) or PSMA-CHAARTED (P = 0.029) or PSMA-LATITUDE (P = 0.009) could achieve PSA 99% reduction faster, and the low and high group patients based on revised-vPGS weren’t displayed the significant difference in PSA99. Through the multivariate Cox survival regression, only MDT scheme (MDT high group vs. low group: HR = 0.47, 95%CI: 0.33–0.69, P < 0.001) was selected as the independent significant prognostic biomarker for mHSPC patients treated with ADT + second-generation ARSIs. Conclusion The visual whole-body tumor-burden classification based on PSMA PET/CT should be an effective stratification strategy for mHSPC patients treated with ADT + ARSIs, especially with ADT + second-generation ARSIs. PSA99 (PSA reduction ≥ 99%) could be a superior endpoint for patients with HSPC. This classification scheme could be a promising method for stratifying mHSPC patients. These findings need to be confirmed and validated through a longer follow-up, prospective and clinical data.
- Open Access
- 23 December 2024
- Published by Springer Nature in Molecular Imaging and Biology
- Vol. 27 (1) , 142-150
68Ga-pentixafor PET/CT Is a Supplementary Method for Primary Aldosteronism Subtyping Compared with Adrenal Vein Sampling
Purpose: To investigate the diagnostic efficacy of 68Ga-pentixafor positron emission tomography/computed tomography (PET/CT) in primary aldosteronism (PA) subtyping and lateralization of aldosterone secretion in PA patients. Procedures: 37 patients who were diagnosed with PA, were prospectively enrolled in the study, and underwent adrenal vein sampling (AVS) after 68Ga-pentixafor PET/CT was conducted. Lateralization index (LI), defined as aldosterone/cortisol ratio in the dominant side to the contralateral adrenal vein when bilateral adrenal vein catheterization succeeded, and the aldosterone/cortisol ratio in the left adrenal vein to IVC (LAV/IVC) when the catheterization of right adrenal vein failed, were applied to determine lateralization side. Statistical analysis was performed using SPSS 21.0. Results: The female proportion of all patients with PA was 32.4% (12/37), and the mean age was 51.3 ± 10.9 years. Patients with bilateral adrenal mass accounted for 54.1% (20/37), and 10 of them (27.0%) had adrenal hyperplasia or adrenal nodules ≤ 1.0 cm. In all 37 patients, the sensitivity, specificity and accuracy of 68Ga-pentixafor PET/CT in distinguishing lateralization by visualization were 89.3%, 77.8% and 86.5%, respectively. The area under the ROC curve for detecting positive lateralization based on the value of 68Ga-pentixafor SUVmax was 0.750 (95%CI 0.578–0.922, p = 0.026). The optimum SUVmax cut-off value was 6.86, with the sensitivity of 78.6%, specificity of 66.7%, and accuracy of 78.4%. Defining SUV ratio as SUVmax/SUV of contralateral adrenal gland, the area under the ROC curve for identifying lateralization based on the SUV ratio was 0.710 (95%CI 0.500–0.921, p = 0.061). The optimum SUV ratio cut-off was 2.40, with the sensitivity of 60.7%, specificity of 88.9%, and accuracy of 67.6%. The consistency of 68Ga-pentixafor PET/CT with AVS was of no significant difference between patients with bilateral adrenal lesions (80.0%, 16/20) and unilateral lesion (94.1%, 16/17; p = 0.737), and no significance was revealed in the consistency between patients with adrenal hyperplasia or adrenal lesion of diameter ≤ 1 cm (81.8%, 9/11) and those with adrenal lesions > 1 cm (88.5%, 23/26; p = 0.884). Conclusions: 68Ga-pentixafor PET/CT showed at least 80% consistency for the lateralization in patients with PA compared with AVS, even in those presented with bilateral adrenal hyperplasia. Visual analysis exhibited better diagnostic efficacy compared with SUVmax or SUVmax/SUV of the contralateral adrenal gland.( ChiCTR2300073049. Registered 30 June 2023. Retrospectively registered)
- 23 December 2024
- Published by Springer Nature in Molecular Imaging and Biology
- Vol. 27 (1) , 142-150
Open Access68Ga-pentixafor PET/CT Is a Supplementary Method for Primary Aldosteronism Subtyping Compared with Adrenal Vein Sampling
Purpose: To investigate the diagnostic efficacy of 68Ga-pentixafor positron emission tomography/computed tomography (PET/CT) in primary aldosteronism (PA) subtyping and lateralization of aldosterone secretion in PA patients. Procedures: 37 patients who were diagnosed with PA, were prospectively enrolled in the study, and underwent adrenal vein sampling (AVS) after 68Ga-pentixafor PET/CT was conducted. Lateralization index (LI), defined as aldosterone/cortisol ratio in the dominant side to the contralateral adrenal vein when bilateral adrenal vein catheterization succeeded, and the aldosterone/cortisol ratio in the left adrenal vein to IVC (LAV/IVC) when the catheterization of right adrenal vein failed, were applied to determine lateralization side. Statistical analysis was performed using SPSS 21.0. Results: The female proportion of all patients with PA was 32.4% (12/37), and the mean age was 51.3 ± 10.9 years. Patients with bilateral adrenal mass accounted for 54.1% (20/37), and 10 of them (27.0%) had adrenal hyperplasia or adrenal nodules ≤ 1.0 cm. In all 37 patients, the sensitivity, specificity and accuracy of 68Ga-pentixafor PET/CT in distinguishing lateralization by visualization were 89.3%, 77.8% and 86.5%, respectively. The area under the ROC curve for detecting positive lateralization based on the value of 68Ga-pentixafor SUVmax was 0.750 (95%CI 0.578–0.922, p = 0.026). The optimum SUVmax cut-off value was 6.86, with the sensitivity of 78.6%, specificity of 66.7%, and accuracy of 78.4%. Defining SUV ratio as SUVmax/SUV of contralateral adrenal gland, the area under the ROC curve for identifying lateralization based on the SUV ratio was 0.710 (95%CI 0.500–0.921, p = 0.061). The optimum SUV ratio cut-off was 2.40, with the sensitivity of 60.7%, specificity of 88.9%, and accuracy of 67.6%. The consistency of 68Ga-pentixafor PET/CT with AVS was of no significant difference between patients with bilateral adrenal lesions (80.0%, 16/20) and unilateral lesion (94.1%, 16/17; p = 0.737), and no significance was revealed in the consistency between patients with adrenal hyperplasia or adrenal lesion of diameter ≤ 1 cm (81.8%, 9/11) and those with adrenal lesions > 1 cm (88.5%, 23/26; p = 0.884). Conclusions: 68Ga-pentixafor PET/CT showed at least 80% consistency for the lateralization in patients with PA compared with AVS, even in those presented with bilateral adrenal hyperplasia. Visual analysis exhibited better diagnostic efficacy compared with SUVmax or SUVmax/SUV of the contralateral adrenal gland.( ChiCTR2300073049. Registered 30 June 2023. Retrospectively registered)
- 1 May 2024
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 49 (7) , 652-654
PSMA and FDG PET/CT Findings in Patient With Dedifferentiated Liposarcoma and Prostate Cancer Metastases
Dedifferentiated liposarcoma is an extremely rare and highly malignant tumor. We demonstrated a case of a 75-year-old man with significantly PSMA-avid and mildly FDG uptake–dedifferentiated liposarcoma in the retroperitoneal area. The double-tracer (PSMA and FDG) PET scans could further contribute to differential diagnosis and the following treatment strategy for patients who were suspected with prostate cancer metastases and other malignant tumors simultaneously.
- 1 May 2024
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 49 (7) , 652-654
PSMA and FDG PET/CT Findings in Patient With Dedifferentiated Liposarcoma and Prostate Cancer Metastases
Dedifferentiated liposarcoma is an extremely rare and highly malignant tumor. We demonstrated a case of a 75-year-old man with significantly PSMA-avid and mildly FDG uptake–dedifferentiated liposarcoma in the retroperitoneal area. The double-tracer (PSMA and FDG) PET scans could further contribute to differential diagnosis and the following treatment strategy for patients who were suspected with prostate cancer metastases and other malignant tumors simultaneously.
- Open Access
- 8 April 2024
- Published by Wiley in Cancer Innovation
- Vol. 3 (2) , e121
18F‐FDG PET/CT findings of paratesticular alveolar rhabdomyosarcoma
Rhabdomyosarcoma (RMS) originates from primitive mesenchymal cells and is the most common soft tissue tumor in childhood. 18F‐fluoro‐deoxyglucose (18F‐FDG) positron emission tomography (PET)/computed tomography (CT) has been reported to be valuable in RMS staging and risk stratification. Paratesticular RMS is a relatively uncommon form of RMS, most of which are of the embryonal histologic type. Paratesticular alveolar RMS is associated with aggressive behavior, high metastatic potential, and poor outcomes. To the best of our knowledge, 18F‐FDG PET/CT imaging findings of paratesticular alveolar RMS have never been described. Here, we report on a 16‐year‐old boy's rare paratesticular alveolar RMS with multiple metastases and its findings on 18F‐FDG PET/CT. This case also demonstrates the potential value of 18F‐FDG PET/CT in RMS staging and treatment decisions, and may aid in the differential diagnosis.
- 8 April 2024
- Published by Wiley in Cancer Innovation
- Vol. 3 (2) , e121
Open Access18F‐FDG PET/CT findings of paratesticular alveolar rhabdomyosarcoma
Rhabdomyosarcoma (RMS) originates from primitive mesenchymal cells and is the most common soft tissue tumor in childhood. 18F‐fluoro‐deoxyglucose (18F‐FDG) positron emission tomography (PET)/computed tomography (CT) has been reported to be valuable in RMS staging and risk stratification. Paratesticular RMS is a relatively uncommon form of RMS, most of which are of the embryonal histologic type. Paratesticular alveolar RMS is associated with aggressive behavior, high metastatic potential, and poor outcomes. To the best of our knowledge, 18F‐FDG PET/CT imaging findings of paratesticular alveolar RMS have never been described. Here, we report on a 16‐year‐old boy's rare paratesticular alveolar RMS with multiple metastases and its findings on 18F‐FDG PET/CT. This case also demonstrates the potential value of 18F‐FDG PET/CT in RMS staging and treatment decisions, and may aid in the differential diagnosis.
- Open Access
- 26 October 2023
- Published by Springer Nature in Scientific Reports
- Vol. 13 (1) , 1-8
Comparison between an SGLT2 inhibitor and insulin in tumor-to-tissue contrasts in 18F-FDG PET imaging of diabetic mice
18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) has been widely utilized for tumor diagnosis. Hyperglycemia affects the 18F-FDG uptake and reduces tumor-to-tissue contrasts, however, ideal hypoglycemic drugs are lacking. This study compared the role of insulin with the novel widely used hypoglycemic drug, sodium-glucose cotransporter 2 (SGLT2) inhibitor, on 18F-FDG PET imaging in diabetic conditions. The streptozotocin (STZ)-induced diabetic C57BL/6N mice were inoculated with B16 (mouse melanoma) cells to establish the xenograft tumor model. After the mice had been administrated with dapagliflozin (30 mg/kg, IG) or insulin (0.75 U/kg, IP) for one hour, 9.25 MBq/10 g 18F-FDG was injected. Biodistributions were detected by gamma counting and microPET imaging. The results showed dapagliflozin did not significantly affect the 18F-FDG uptake in tumors but reduced uptake in reference tissues, resulting in a significant increase in the tumor-to-skeletal muscle ratio. Conversely, insulin increased 18F-FDG uptake in tumors without significant reduction in uptake in reference tissues; Although there was an observable improvement in tumor imaging, it did not reach significantly statistical differences. This study suggests that insulin and SGLT2 inhibitor yield comparable effects on the quality of 18F-FDG PET imaging in diabetic patients. Nevertheless, SGLT2 inhibitors would be more suitable when skeletal muscle is used as reference tissue.
- 26 October 2023
- Published by Springer Nature in Scientific Reports
- Vol. 13 (1) , 1-8
Open AccessComparison between an SGLT2 inhibitor and insulin in tumor-to-tissue contrasts in 18F-FDG PET imaging of diabetic mice
18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) has been widely utilized for tumor diagnosis. Hyperglycemia affects the 18F-FDG uptake and reduces tumor-to-tissue contrasts, however, ideal hypoglycemic drugs are lacking. This study compared the role of insulin with the novel widely used hypoglycemic drug, sodium-glucose cotransporter 2 (SGLT2) inhibitor, on 18F-FDG PET imaging in diabetic conditions. The streptozotocin (STZ)-induced diabetic C57BL/6N mice were inoculated with B16 (mouse melanoma) cells to establish the xenograft tumor model. After the mice had been administrated with dapagliflozin (30 mg/kg, IG) or insulin (0.75 U/kg, IP) for one hour, 9.25 MBq/10 g 18F-FDG was injected. Biodistributions were detected by gamma counting and microPET imaging. The results showed dapagliflozin did not significantly affect the 18F-FDG uptake in tumors but reduced uptake in reference tissues, resulting in a significant increase in the tumor-to-skeletal muscle ratio. Conversely, insulin increased 18F-FDG uptake in tumors without significant reduction in uptake in reference tissues; Although there was an observable improvement in tumor imaging, it did not reach significantly statistical differences. This study suggests that insulin and SGLT2 inhibitor yield comparable effects on the quality of 18F-FDG PET imaging in diabetic patients. Nevertheless, SGLT2 inhibitors would be more suitable when skeletal muscle is used as reference tissue.
- Open Access
- 5 April 2023
- Published by Springer Nature in BMC Medical Imaging
- Vol. 23 (1) , 1-12
The value on SUV-derived parameters assessed on 18F-FDG PET/CT for predicting mediastinal lymph node metastasis in non-small cell lung cancer
Purpose: To explore valuable predictors for mediastinal lymph node metastasis in non-small cell lung cancer (NSCLC) patients, we analyzed the potential roles of standardized uptake value (SUV)-derived parameters from preoperative 18F-FDG PET/CT combined with clinical characteristics. Methods: Data from 224 NSCLC patients who underwent preoperative 18F-FDG PET/CT scans in our hospital were collected. Then, a series of clinical parameters including SUV-derived features [SUVmax of mediastinal lymph node and primary-tumor SUVmax, SUVpeak, SUVmean, metabolic tumor volume (MTV) and total lesion glycolysis (TLG)] were evaluated. The best possible cutoff points for all measuring parameters were calculated using receiver operating characteristic curve (ROC) analysis. Predictive analyses were performed using a Logistic regression model to determine the predictive factors for mediastinal lymph node metastasis in NSCLC and lung adenocarcinoma patients. After multivariate model construction, data of another 100 NSCLC patients were recorded. Then, 224 patients and 100 patients were enrolled to validate the predictive model by the area under the receiver operating characteristic curve (AUC). Results: The mediastinal lymph node metastasis rates in 224 patients for model construction and 100 patients for model validation were 24.1% (54/224) and 25% (25/100), respectively. It was found that SUVmax of mediastinal lymph node ≥ 2.49, primary-tumor SUVmax ≥ 4.11, primary-tumor SUVpeak ≥ 2.92, primary-tumor SUVmean ≥ 2.39, primary-tumor MTV ≥ 30.88 cm3, and primary-tumor TLG ≥ 83.53 were more prone to mediastinal lymph node metastasis through univariate logistic regression analyses. The multivariate logistic regression analyses showed that the SUVmax of mediastinal lymph nodes (≥ 2.49: OR 7.215, 95% CI 3.326–15.649), primary-tumor SUVpeak (≥ 2.92: OR 5.717, 95% CI 2.094–15.605), CEA (≥ 3.94 ng/ml: OR 2.467, 95% CI 1.182–5.149), and SCC (< 1.15 ng/ml: OR 4.795, 95% CI 2.019–11.388) were independent predictive factors for lymph node metastasis in the mediastinum. It was found that SUVmax of the mediastinal lymph node (≥ 2.49: OR 8.067, 95% CI 3.193–20.383), primary-tumor SUVpeak (≥ 2.92: OR 9.219, 95% CI 3.096–27.452), and CA19-9 (≥ 16.6 U/ml: OR 3.750, 95% CI 1.485–9.470) were significant predictive factors for mediastinal lymph node metastasis in lung adenocarcinoma patients. The AUCs for the predictive value of the NSCLC multivariate model through internal and external validation were 0.833 (95% CI 0.769- 0.896) and 0.811 (95% CI 0.712–0.911), respectively. Conclusion: High SUV-derived parameters (SUVmax of mediastinal lymph node and primary-tumor SUVmax, SUVpeak, SUVmean, MTV and TLG) might provide varying degrees of predictive value for mediastinal lymph node metastasis in NSCLC patients. In particular, the SUVmax of mediastinal lymph nodes and primary-tumor SUVpeak could be independently and significantly associated with mediastinal lymph node metastasis in NSCLC and lung adenocarcinoma patients. Internal and external validation confirmed that the pretherapeutic SUVmax of the mediastinal lymph node and primary-tumor SUVpeak combined with serum CEA and SCC can effectively predict mediastinal lymph node metastasis of NSCLC patients.
- 5 April 2023
- Published by Springer Nature in BMC Medical Imaging
- Vol. 23 (1) , 1-12
Open AccessThe value on SUV-derived parameters assessed on 18F-FDG PET/CT for predicting mediastinal lymph node metastasis in non-small cell lung cancer
Purpose: To explore valuable predictors for mediastinal lymph node metastasis in non-small cell lung cancer (NSCLC) patients, we analyzed the potential roles of standardized uptake value (SUV)-derived parameters from preoperative 18F-FDG PET/CT combined with clinical characteristics. Methods: Data from 224 NSCLC patients who underwent preoperative 18F-FDG PET/CT scans in our hospital were collected. Then, a series of clinical parameters including SUV-derived features [SUVmax of mediastinal lymph node and primary-tumor SUVmax, SUVpeak, SUVmean, metabolic tumor volume (MTV) and total lesion glycolysis (TLG)] were evaluated. The best possible cutoff points for all measuring parameters were calculated using receiver operating characteristic curve (ROC) analysis. Predictive analyses were performed using a Logistic regression model to determine the predictive factors for mediastinal lymph node metastasis in NSCLC and lung adenocarcinoma patients. After multivariate model construction, data of another 100 NSCLC patients were recorded. Then, 224 patients and 100 patients were enrolled to validate the predictive model by the area under the receiver operating characteristic curve (AUC). Results: The mediastinal lymph node metastasis rates in 224 patients for model construction and 100 patients for model validation were 24.1% (54/224) and 25% (25/100), respectively. It was found that SUVmax of mediastinal lymph node ≥ 2.49, primary-tumor SUVmax ≥ 4.11, primary-tumor SUVpeak ≥ 2.92, primary-tumor SUVmean ≥ 2.39, primary-tumor MTV ≥ 30.88 cm3, and primary-tumor TLG ≥ 83.53 were more prone to mediastinal lymph node metastasis through univariate logistic regression analyses. The multivariate logistic regression analyses showed that the SUVmax of mediastinal lymph nodes (≥ 2.49: OR 7.215, 95% CI 3.326–15.649), primary-tumor SUVpeak (≥ 2.92: OR 5.717, 95% CI 2.094–15.605), CEA (≥ 3.94 ng/ml: OR 2.467, 95% CI 1.182–5.149), and SCC (< 1.15 ng/ml: OR 4.795, 95% CI 2.019–11.388) were independent predictive factors for lymph node metastasis in the mediastinum. It was found that SUVmax of the mediastinal lymph node (≥ 2.49: OR 8.067, 95% CI 3.193–20.383), primary-tumor SUVpeak (≥ 2.92: OR 9.219, 95% CI 3.096–27.452), and CA19-9 (≥ 16.6 U/ml: OR 3.750, 95% CI 1.485–9.470) were significant predictive factors for mediastinal lymph node metastasis in lung adenocarcinoma patients. The AUCs for the predictive value of the NSCLC multivariate model through internal and external validation were 0.833 (95% CI 0.769- 0.896) and 0.811 (95% CI 0.712–0.911), respectively. Conclusion: High SUV-derived parameters (SUVmax of mediastinal lymph node and primary-tumor SUVmax, SUVpeak, SUVmean, MTV and TLG) might provide varying degrees of predictive value for mediastinal lymph node metastasis in NSCLC patients. In particular, the SUVmax of mediastinal lymph nodes and primary-tumor SUVpeak could be independently and significantly associated with mediastinal lymph node metastasis in NSCLC and lung adenocarcinoma patients. Internal and external validation confirmed that the pretherapeutic SUVmax of the mediastinal lymph node and primary-tumor SUVpeak combined with serum CEA and SCC can effectively predict mediastinal lymph node metastasis of NSCLC patients.
- Open Access
- 19 January 2023
- Published by Springer Nature in Research Square
The value on SUV-derived parameters assessed on 18F-FDG PET/CT for predicting mediastinal lymph node metastasis in non-small cell lung cancer
Purpose: To explore valuable predictors for mediastinal lymph node metastasis in non-small cell lung cancer (NSCLC) patients, we analyzed the potential roles of standardized uptake value (SUV)-derived parameters from preoperative 18F-FDG PET/CT combined with clinical characteristics. Methods: Data from 224 NSCLC patients who underwent preoperative 18F-FDG PET/CT scans in our hospital were collected. Then, a series of clinical parameters including SUV-derived features [SUVmax of mediastinal lymph node and primary-tumor SUVmax, SUVpeak, SUVmean, metabolic tumor volume (MTV) and total lesion glycolysis (TLG)] were evaluated. The best possible cutoff points for all measuring parameters were calculated using receiver operating characteristic curve (ROC) analysis. Predictive analyses were performed using a logistic regression model to determine the predictive factors for mediastinal lymph node metastasis in NSCLC and lung adenocarcinoma patients. After multivariate model construction, data from another 100 NSCLC patients were recorded. Then, 224 patients and 100 patients were enrolled to validate the predictive model by the area under the receiver operating characteristic curve (AUC). Results: The mediastinal lymph node metastasis rates in 224 patients for model construction and 100 patients for model validation were 24.1% (54/224) and 25% (25/100), respectively. It was found that SUVmax of mediastinal lymph node, primary-tumor SUVpeak ≥ 2.49, primary-tumor SUVmax ≥ 4.11, primary-tumor SUVpeak ≥ 2.92, primary-tumor SUVmean ≥ 2.39, primary-tumor MTV ≥ 30.88 cm3, and primary-tumor TLG ≥ 85.53 were more prone to mediastinal lymph node metastasis through univariate logistic regression analyses. The multivariate logistic regression analyses showed that the SUVmax of mediastinal lymph nodes (≥ 2.49: HR = 7.215, 95% CI: 3.326 - 15.649), primary tumor SUVpeak (≥ 4.11: HR = 5.717, 95% CI: 2.094 - 15.605), CEA (≥ 3.94 ng/ml: HR = 2.467, 95% CI: 1.182 - 5.149), and SCC (< 1.15 ng/ml: HR = 4.795, 95% CI: 2.019 - 11.388) were independent predictive factors for lymph node metastasis in the mediastinum. SUVmax of the mediastinal lymph node (≥ 2.49: HR = 8.067, 95% CI: 3.193 - 20.383), primary-tumor SUVpeak (≥ 4.11: HR = 9.219, 95% CI: 3.096 - 27.452), and CA19-9 (≥ 16.6 U/ml: HR = 3.750, 95% CI: 1.485 - 9.470) were significant predictive factors for mediastinal lymph node metastasis in lung adenocarcinoma patients. The AUCs for the predictive value of the NSCLC multivariate model through internal and external validation were 0.833 (95% CI: 0.769- 0.896) and 0.811 (95% CI: 0.712 - 0.911), respectively. Conclusion: High SUV-derived parameters (SUVmax of mediastinal lymph node and primary-tumor SUVmax, SUVpeak, SUVmean, MTV and TLG) might provide varying degrees of predictive value for mediastinal lymph node metastasis in NSCLC patients. In particular, the SUVmax of mediastinal lymph nodes and primary tumor SUVpeak could be independently and significantly associated with mediastinal lymph node metastasis in NSCLC and lung adenocarcinoma patients. Internal and external validation confirmed that the pretherapeutic SUVmax of the mediastinal lymph node and primary-tumor SUVpeak combined with serum CEA and SCC can effectively predict mediastinal lymph node metastasis.
- 19 January 2023
- Published by Springer Nature in Research Square
Open AccessThe value on SUV-derived parameters assessed on 18F-FDG PET/CT for predicting mediastinal lymph node metastasis in non-small cell lung cancer
Purpose: To explore valuable predictors for mediastinal lymph node metastasis in non-small cell lung cancer (NSCLC) patients, we analyzed the potential roles of standardized uptake value (SUV)-derived parameters from preoperative 18F-FDG PET/CT combined with clinical characteristics. Methods: Data from 224 NSCLC patients who underwent preoperative 18F-FDG PET/CT scans in our hospital were collected. Then, a series of clinical parameters including SUV-derived features [SUVmax of mediastinal lymph node and primary-tumor SUVmax, SUVpeak, SUVmean, metabolic tumor volume (MTV) and total lesion glycolysis (TLG)] were evaluated. The best possible cutoff points for all measuring parameters were calculated using receiver operating characteristic curve (ROC) analysis. Predictive analyses were performed using a logistic regression model to determine the predictive factors for mediastinal lymph node metastasis in NSCLC and lung adenocarcinoma patients. After multivariate model construction, data from another 100 NSCLC patients were recorded. Then, 224 patients and 100 patients were enrolled to validate the predictive model by the area under the receiver operating characteristic curve (AUC). Results: The mediastinal lymph node metastasis rates in 224 patients for model construction and 100 patients for model validation were 24.1% (54/224) and 25% (25/100), respectively. It was found that SUVmax of mediastinal lymph node, primary-tumor SUVpeak ≥ 2.49, primary-tumor SUVmax ≥ 4.11, primary-tumor SUVpeak ≥ 2.92, primary-tumor SUVmean ≥ 2.39, primary-tumor MTV ≥ 30.88 cm3, and primary-tumor TLG ≥ 85.53 were more prone to mediastinal lymph node metastasis through univariate logistic regression analyses. The multivariate logistic regression analyses showed that the SUVmax of mediastinal lymph nodes (≥ 2.49: HR = 7.215, 95% CI: 3.326 - 15.649), primary tumor SUVpeak (≥ 4.11: HR = 5.717, 95% CI: 2.094 - 15.605), CEA (≥ 3.94 ng/ml: HR = 2.467, 95% CI: 1.182 - 5.149), and SCC (< 1.15 ng/ml: HR = 4.795, 95% CI: 2.019 - 11.388) were independent predictive factors for lymph node metastasis in the mediastinum. SUVmax of the mediastinal lymph node (≥ 2.49: HR = 8.067, 95% CI: 3.193 - 20.383), primary-tumor SUVpeak (≥ 4.11: HR = 9.219, 95% CI: 3.096 - 27.452), and CA19-9 (≥ 16.6 U/ml: HR = 3.750, 95% CI: 1.485 - 9.470) were significant predictive factors for mediastinal lymph node metastasis in lung adenocarcinoma patients. The AUCs for the predictive value of the NSCLC multivariate model through internal and external validation were 0.833 (95% CI: 0.769- 0.896) and 0.811 (95% CI: 0.712 - 0.911), respectively. Conclusion: High SUV-derived parameters (SUVmax of mediastinal lymph node and primary-tumor SUVmax, SUVpeak, SUVmean, MTV and TLG) might provide varying degrees of predictive value for mediastinal lymph node metastasis in NSCLC patients. In particular, the SUVmax of mediastinal lymph nodes and primary tumor SUVpeak could be independently and significantly associated with mediastinal lymph node metastasis in NSCLC and lung adenocarcinoma patients. Internal and external validation confirmed that the pretherapeutic SUVmax of the mediastinal lymph node and primary-tumor SUVpeak combined with serum CEA and SCC can effectively predict mediastinal lymph node metastasis.
- 26 November 2022
- Published by Taylor & Francis in Nanotoxicology
- Vol. 16 (9-10) , 895-912
Evaluation of cytotoxicity and biodistribution of mesoporous carbon nanotubes (pristine/-OH/-COOH) to HepG2 cells in vitro and healthy mice in vivo
Mesoporous carbon nanotubes (mCNTs) hold great promise interests, owing to their superior nano-platform properties for biomedicine. To fully utilize this potential, the toxicity and biodistribution of pristine and surface-modified mCNTs (-OH/-COOH) should preferentially be addressed. The results of cell viability suggested that pristine mCNTs induced cell death in a concentration-dependent manner. As evidence of reactive oxygen species (ROS), malondialdehyde (MDA) and superoxide dismutase (SOD), pristine mCNTs induced noticeable redox imbalance. 99mTc tracing data suggested that the cellular uptake of pristine mCNTs posed a concentrate-dependent and energy-dependent manner via macropinocytotic and clathrin-dependent pathways, and the main accumulated organs were lung, liver and spleen. With OH modification, the ROS generation, MDA deposition and SOD consumption were evidently reduced compared with the pristine mCNTs at 24/48 h high-dose exposure. With COOH modification, the modified mCNTs only showed a significant difference in SOD consumption at 24/48 h exposure, but there was no significant difference in the measurement of ROS and MDA. The internalization mechanism and organ distribution of modified mCNTs were basically invariant. Together, our study provides evidence that mCNTs and the modified mCNTs all could induce oxidative damage and thereby impair cells. 99mTc-mCNTs can effectively trace the distribution of nanotubes in vivo.
- 26 November 2022
- Published by Taylor & Francis in Nanotoxicology
- Vol. 16 (9-10) , 895-912
Evaluation of cytotoxicity and biodistribution of mesoporous carbon nanotubes (pristine/-OH/-COOH) to HepG2 cells in vitro and healthy mice in vivo
Mesoporous carbon nanotubes (mCNTs) hold great promise interests, owing to their superior nano-platform properties for biomedicine. To fully utilize this potential, the toxicity and biodistribution of pristine and surface-modified mCNTs (-OH/-COOH) should preferentially be addressed. The results of cell viability suggested that pristine mCNTs induced cell death in a concentration-dependent manner. As evidence of reactive oxygen species (ROS), malondialdehyde (MDA) and superoxide dismutase (SOD), pristine mCNTs induced noticeable redox imbalance. 99mTc tracing data suggested that the cellular uptake of pristine mCNTs posed a concentrate-dependent and energy-dependent manner via macropinocytotic and clathrin-dependent pathways, and the main accumulated organs were lung, liver and spleen. With OH modification, the ROS generation, MDA deposition and SOD consumption were evidently reduced compared with the pristine mCNTs at 24/48 h high-dose exposure. With COOH modification, the modified mCNTs only showed a significant difference in SOD consumption at 24/48 h exposure, but there was no significant difference in the measurement of ROS and MDA. The internalization mechanism and organ distribution of modified mCNTs were basically invariant. Together, our study provides evidence that mCNTs and the modified mCNTs all could induce oxidative damage and thereby impair cells. 99mTc-mCNTs can effectively trace the distribution of nanotubes in vivo.